ABL1 and acute lymphoblastic leukemia: Notably, the dose-dependent reduction in cell viability was confirmed in primary blast cells from two Ph+ ALL patients with the T315I BCR-ABL1 kinase domain mutation, which is responsible for resistance to currently available TKIs (Figure 2F).